Search

This workshop on "How to publish your research" is delivered by the British Journal of Biomedical Science team. The aim of the workshop is to provide attendees with a clear understanding of the publishing process, so they feel empowered to submit their research to a peer-reviewed journal. As the British Journal of Biomedical Science is the official journal of the IBMS the workshop will provide members with the opportunity to discuss how they can engage with their journal.

How to report staining intensity for flow cytometry EQA exercises

How to train your dragon . . . not to harm your workforce

Idiopathic Membranous Nephropathy: PLA2 and beyond

IIF and Artificial Intelligence

Implementing a new laboratory IT system and how to avoid the pitfalls

Interpretation of ISAC

Coagulopathy has been shown to play an important role in COVID 19 infection. Reported abnormal coagulation laboratory values in severe COVID-19 are most notably a 3-to-4-fold increase in D-Dimer (Yao et al., 2020).

Several studies showed that elevated D-dimer in COVID-19 patients is associated with higher mortality. A retrospective cohort study carried out by Zhou, et al. (2020) also associated D-Dimer > 1000ng/ml with higher odds of in-patient death.

At the onset of the COVID 19 pandemic, there was no consensus as to how D-Dimer levels should be used for the management of COVID-19 patients. In April 2020, PAHT decided to use a D-Dimer cut-off of 1000 ng/ml to determine anticoagulation dosage. The source of reference used by PAHT in their decision making employed a D-Dimer assay with a cut off value of 500 ng/ml for the exclusion of venous thromboembolism (VTE). This raised an issue as the source of reference used by PAHT at the time employed a D Dimer assay with a cut-off value of 230 ng/ml for the exclusion of VTE. This meant the trust was unable to implement the new COVID 19 care bundle at the time. The haematology laboratory wanting to do whatever possible to assist patient care agreed to change the current D-Dimer methodology immediately to support the trust COVID 19 care bundle.

The verification and implementation of the new D-Dimer assay with cut of 500 ng/ml for the exclusion of VTE was completed within four weeks. A risk assessment and a change control were put in place to ensure users were made aware of the change in cut-off limit.

This verification and implementation of the new assay was possible through the hard and collaborative work of the haematology technical team with shared vision, motivation coupled with team engagement and strong leadership.

A case study into iron deficiency polycythaemia diagnosis, looking at the pathology and how this relates to the results we see and investigations to confirm diagnosis.

Global travel and migration trends have meant a huge increase in the numbers of people exposed to tropical parasitic diseases. Thus, there is an increasing need for robust, reproducible and reliable screening as well as diagnostic techniques. These existing and emerging technologies all currently co-exist; each with their own specific and general pitfalls and limitations.

Thus, the need for fit-for-purpose qualitative EQAs or Proficiency Testing schemes for these parasite diagnostics remains pivotal and very timely. My talk at this congress will present findings and recommendations from Parasitology EQA schemes offered by UK NEQAS and will highlight the importance of quality management in the field.